SCHEMBL2649124

SCHEMBL2649124

CNS(=O)(=O)c1sc(NC(=O)N(C2CCCCC2)[C@H]2CC[C@H](C)CC2)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PI4KB Q9UBF8 5/20 0.36
LMNA P02545 1/20 0.35
ALDH1A1 P00352 2/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
RORA P35398 1/20 0.33
RORC P51449 1/20 0.33
RORB Q92753 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA5A P35218 1/20 0.32
CA9 Q16790 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649128 1.00 NPC1 (0.39) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2660704 0.89 NPC1 (0.41) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2660706 0.89 NPC1 (0.41) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2648881 0.87 RAB9A (0.36) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2648875 0.87 RAB9A (0.36) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2653751 0.83 NPC1 (0.45) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2649132 0.82 DPP4 (0.37) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2649135 0.82 DPP4 (0.37) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL1002330 0.81 NPC1 (0.39) NPC1RAB9ASMN1; SMN2PI4KBLMNA
SCHEMBL2647848 0.81 CA2 (0.51) LMNACA12CA1CA2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 NPC1 2090/4885RAB9A 2950/4885SMN1; SMN2 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.